Logo image of TRDA

ENTRADA THERAPEUTICS INC (TRDA) Stock Fundamental Analysis

NASDAQ:TRDA - Nasdaq - US29384C1080 - Common Stock - Currency: USD

7.23  -0.04 (-0.55%)

After market: 7.23 0 (0%)

Fundamental Rating

4

TRDA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. TRDA has an excellent financial health rating, but there are some minor concerns on its profitability. TRDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year TRDA was profitable.
TRDA had a negative operating cash flow in the past year.
TRDA had negative earnings in 4 of the past 5 years.
TRDA had negative operating cash flow in 4 of the past 5 years.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

TRDA's Return On Assets of 5.09% is amongst the best of the industry. TRDA outperforms 92.07% of its industry peers.
With an excellent Return On Equity value of 5.94%, TRDA belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
TRDA has a Return On Invested Capital of 0.69%. This is amongst the best in the industry. TRDA outperforms 91.71% of its industry peers.
Industry RankSector Rank
ROA 5.09%
ROE 5.94%
ROIC 0.69%
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

Looking at the Profit Margin, with a value of 14.39%, TRDA belongs to the top of the industry, outperforming 93.69% of the companies in the same industry.
With an excellent Operating Margin value of 2.39%, TRDA belongs to the best of the industry, outperforming 92.25% of the companies in the same industry.
Industry RankSector Rank
OM 2.39%
PM (TTM) 14.39%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TRDA is destroying value.
TRDA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TRDA has more shares outstanding
TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

TRDA has an Altman-Z score of 3.30. This indicates that TRDA is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.30, TRDA is doing good in the industry, outperforming 73.69% of the companies in the same industry.
TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.3
ROIC/WACC0.08
WACC8.93%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

TRDA has a Current Ratio of 21.88. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 21.88, TRDA belongs to the top of the industry, outperforming 94.77% of the companies in the same industry.
A Quick Ratio of 21.88 indicates that TRDA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 21.88, TRDA belongs to the top of the industry, outperforming 94.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.88
Quick Ratio 21.88
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.57% over the past year.
The Revenue has been growing slightly by 5.74% in the past year.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
Revenue 1Y (TTM)5.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.23%

3.2 Future

Based on estimates for the next years, TRDA will show a very strong growth in Earnings Per Share. The EPS will grow by 34.13% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-268.89%
EPS Next 2Y-106.63%
EPS Next 3Y-59.93%
EPS Next 5Y34.13%
Revenue Next Year-74.92%
Revenue Next 2Y-59.59%
Revenue Next 3Y-32.87%
Revenue Next 5Y-14.87%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2030 50M 100M 150M 200M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 8.93, which indicates a very decent valuation of TRDA.
Based on the Price/Earnings ratio, TRDA is valued cheaply inside the industry as 97.48% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.28. TRDA is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for TRDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 8.93
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -53.38
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

TRDA's earnings are expected to decrease with -59.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-106.63%
EPS Next 3Y-59.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (7/3/2025, 1:30:01 PM)

After market: 7.23 0 (0%)

7.23

-0.04 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners78.07%
Inst Owner Change-1.52%
Ins Owners0.79%
Ins Owner Change23.8%
Market Cap274.38M
Analysts85.45
Price Target20.91 (189.21%)
Short Float %3.39%
Short Ratio7.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.1%
Min EPS beat(2)47.81%
Max EPS beat(2)104.39%
EPS beat(4)4
Avg EPS beat(4)288.27%
Min EPS beat(4)47.81%
Max EPS beat(4)948.01%
EPS beat(8)6
Avg EPS beat(8)190.15%
EPS beat(12)7
Avg EPS beat(12)116.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)138.81%
Min Revenue beat(2)98.17%
Max Revenue beat(2)179.44%
Revenue beat(4)4
Avg Revenue beat(4)108.71%
Min Revenue beat(4)55.73%
Max Revenue beat(4)179.44%
Revenue beat(8)8
Avg Revenue beat(8)153%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.75%
PT rev (3m)-22.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.41%
EPS NY rev (1m)2.27%
EPS NY rev (3m)-2.33%
Revenue NQ rev (1m)-3.74%
Revenue NQ rev (3m)-13.6%
Revenue NY rev (1m)17.83%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE 8.93
Fwd PE N/A
P/S 1.59
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA -53.38
EPS(TTM)0.81
EY11.2%
EPS(NY)-4.33
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS4.54
BVpS10.99
TBVpS11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.09%
ROE 5.94%
ROCE 0.88%
ROIC 0.69%
ROICexc 3.79%
ROICexgc 3.79%
OM 2.39%
PM (TTM) 14.39%
GM N/A
FCFM N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 91.52%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.88
Quick Ratio 21.88
Altman-Z 3.3
F-Score5
WACC8.93%
ROIC/WACC0.08
Cap/Depr(3y)144.47%
Cap/Depr(5y)309.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
EPS Next Y-268.89%
EPS Next 2Y-106.63%
EPS Next 3Y-59.93%
EPS Next 5Y34.13%
Revenue 1Y (TTM)5.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.23%
Revenue Next Year-74.92%
Revenue Next 2Y-59.59%
Revenue Next 3Y-32.87%
Revenue Next 5Y-14.87%
EBIT growth 1Y-82.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-736.79%
EBIT Next 3Y-107.2%
EBIT Next 5YN/A
FCF growth 1Y-145.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.76%
OCF growth 3YN/A
OCF growth 5YN/A